OKYO Pharma (NASDAQ:OKYO) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen upgraded shares of OKYO Pharma (NASDAQ:OKYO) to a hold rating in a research report report published on Saturday.

Separately, HC Wainwright reiterated a “buy” rating and set a $7.00 target price on shares of OKYO Pharma in a report on Monday, May 5th.

OKYO Pharma Trading Down 4.6%

Shares of NASDAQ:OKYO opened at $3.12 on Friday. The business’s fifty day moving average price is $2.64 and its two-hundred day moving average price is $1.78. OKYO Pharma has a one year low of $0.85 and a one year high of $3.35.

Institutional Investors Weigh In On OKYO Pharma

Several hedge funds have recently made changes to their positions in OKYO. Dauntless Investment Group LLC acquired a new stake in shares of OKYO Pharma during the first quarter worth $2,526,000. FNY Investment Advisers LLC purchased a new position in shares of OKYO Pharma in the 1st quarter worth $25,000. Finally, Wealth Enhancement Advisory Services LLC purchased a new position in shares of OKYO Pharma in the 2nd quarter worth $28,000. Institutional investors and hedge funds own 2.97% of the company’s stock.

OKYO Pharma Company Profile

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.